Current Issue

July 19, 2018: 132 (3)
Blood: 132 (3)

First Edition


  • Review Series: Emerging Immunotherapies for Hematologic Diseases

    Catherine M. Bollard, MBChB, MD, and Leslie S. Kean, MD, PhD, share highlights of this review series that highlights chimeric antigen receptor T cells and their toxicities, vaccine therapies, and cellular therapies for graft-versus-host disease.

  • Review Series: Update on Hodgkin Lymphoma

    Introduced with an editorial by Blood Associate Editor Laurie H. Sehn, the articles in this series of reviews on Hodgkin lymphoma explore advances in biological insights that have led to the identification of novel targets for drug development and enabled more accurate prognostication. They also examine optimization of various therapeutic strategies for early-stage, advanced-stage, and relapsed disease.

  • Review Series: Strategies to Improve GVL Effects

    Robert Zeiser, MD, and Michel Sadelain, MD, PhD discuss highlights of this review series which explores exciting new developments in treatments to enhance graft-versus-leukemia (GVL) effects in hematopoietic cell transplantation, including cellular therapies, antibody-based treatments, and drug-based approaches using tyrosine kinase inhibitors and checkpoint blockade